At a glance
- Originator Sumitomo Pharmaceuticals
- Class Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 1998 No-Development-Reported for Cancer in Japan (Unknown route)
- 03 Nov 1994 Preclinical development for Cancer in Japan (Unknown route)